Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Testosterone and dihydrotestosterone have similar effects on body composition and metabolic health in men.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

Oral cyclosporine combined with Pantogar® effectively treats twenty-nail dystrophy.

High triglyceride levels are a key factor affecting testosterone levels in women with PCOS.

Fractional Er:YAG laser with PRP is more effective and has fewer side effects than microneedling with PRP for vitiligo.

AI can accurately measure hair loss severity in alopecia areata.

Biodegradable microneedle patches help topical steroids work better for prurigo nodularis.

Clonally expanded CD8+ T cells cause alopecia areata.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Finasteride reduces prostate cancer risk by 30% without affecting Gleason scores.

A new gene location for Keratosis follicularis squamosa was found on chromosome 7p14.3-7p12.1.

Self-assessed hirsutism scores are not reliable for clinical diagnosis but may help in screening.

Cryotherapy and steroid injections are similarly effective and safe for treating alopecia areata.

Fetal skin has unique immune cells different from adult skin.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.

STS01 1% effectively promotes hair regrowth with minimal side effects.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.

Genetics can help tailor treatments for male pattern hair loss, improving outcomes like stabilization or modest regrowth.

Lower DHT and higher testosterone levels increase brain activation but don't change behavior in heavy drinkers.

Ustekinumab and vedolizumab can help some ulcerative colitis patients with hair regrowth, but results vary.

IFN-γ production by CD4 T cells is crucial for causing alopecia areata.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

New pyrazole derivatives may help treat hair loss, but more testing is needed.

Chronic granulomatous disease may be linked to developing systemic lupus erythematosus.

Baricitinib is more effective than methotrexate for severe alopecia areata.